REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of non-implant, catheter-based, leaflet modification solutions for treating heart valves, announced today it ...
REHOVOT, Israel--(BUSINESS WIRE)--Pi-Cardia Ltd., a global leader in the development of leaflet modification solutions for treating heart valves, announced today that the United States Food and Drug ...
Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...
The Pi-Cardia Ltd. Shortcut — the catheter-based, leaflet modification solution for treating heart valves — received U.S. FDA clearance. The device was granted breakthrough device designation from the ...
The FDA has granted a de novo clearance to Pi-Cardia’s ShortCut device, designed to open up previously implanted heart valves and clear a path for blood to flow into the coronary arteries, allowing ...
PARIS -- For people undergoing valve-in-valve transcatheter aortic valve replacement (TAVR), a dedicated bioprosthetic leaflet splitting device produced better-than-expected results preventing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results